Clinical TrialsProMIS received approval from the independent Data and Safety Monitoring Board to advance to the final dose escalation cohort in its ongoing P1b study of PMN310 for Alzheimer's disease.
Financial HealthProMIS has strengthened its balance sheet by raising $21.6M in gross proceeds and launching an ~$18M ATM offering, providing funding into 2026.
Regulatory ApprovalsPMN310 received Fast Track Designation for early Alzheimer's treatment, potentially accelerating its approval process.